vs

Side-by-side financial comparison of CISO Global, Inc. (CISO) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

Avidity Biosciences, Inc. is the larger business by last-quarter revenue ($12.5M vs $6.3M, roughly 2.0× CISO Global, Inc.). CISO Global, Inc. runs the higher net margin — -35.4% vs -1398.3%, a 1363.0% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs -15.4%). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs -11.6%).

CISO Global, Inc. is a specialized cybersecurity services provider. It offers managed security monitoring, risk assessment, compliance advisory and incident response, serving North American SMEs, government and commercial clients across healthcare, retail and finance to help safeguard digital assets and mitigate cyber risks.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

CISO vs RNA — Head-to-Head

Bigger by revenue
RNA
RNA
2.0× larger
RNA
$12.5M
$6.3M
CISO
Growing faster (revenue YoY)
RNA
RNA
+449.4% gap
RNA
434.0%
-15.4%
CISO
Higher net margin
CISO
CISO
1363.0% more per $
CISO
-35.4%
-1398.3%
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
-11.6%
CISO

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
CISO
CISO
RNA
RNA
Revenue
$6.3M
$12.5M
Net Profit
$-2.2M
$-174.4M
Gross Margin
28.6%
Operating Margin
-33.7%
-1513.5%
Net Margin
-35.4%
-1398.3%
Revenue YoY
-15.4%
434.0%
Net Profit YoY
59.8%
-117.0%
EPS (diluted)
$0.10
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CISO
CISO
RNA
RNA
Q4 25
$6.3M
Q3 25
$6.5M
$12.5M
Q2 25
$6.7M
$3.8M
Q1 25
$7.2M
$1.6M
Q4 24
$7.4M
$3.0M
Q3 24
$7.5M
$2.3M
Q2 24
$7.8M
$2.0M
Q1 24
$8.0M
$3.5M
Net Profit
CISO
CISO
RNA
RNA
Q4 25
$-2.2M
Q3 25
$2.5M
$-174.4M
Q2 25
$-3.0M
$-157.3M
Q1 25
$-5.4M
$-115.8M
Q4 24
$-5.5M
$-102.3M
Q3 24
$-3.7M
$-80.4M
Q2 24
$-8.4M
$-70.8M
Q1 24
$-6.6M
$-68.9M
Gross Margin
CISO
CISO
RNA
RNA
Q4 25
28.6%
Q3 25
24.9%
Q2 25
24.4%
Q1 25
24.9%
Q4 24
24.8%
Q3 24
13.8%
Q2 24
12.0%
Q1 24
8.8%
Operating Margin
CISO
CISO
RNA
RNA
Q4 25
-33.7%
Q3 25
-40.8%
-1513.5%
Q2 25
-34.7%
-4448.7%
Q1 25
-23.9%
-8360.9%
Q4 24
-26.1%
-4069.6%
Q3 24
-46.8%
-4200.9%
Q2 24
-54.3%
-4040.4%
Q1 24
-61.0%
-2178.6%
Net Margin
CISO
CISO
RNA
RNA
Q4 25
-35.4%
Q3 25
39.2%
-1398.3%
Q2 25
-44.8%
-4089.3%
Q1 25
-75.1%
-7360.0%
Q4 24
-74.5%
-3439.5%
Q3 24
-49.0%
-3441.7%
Q2 24
-108.0%
-3461.8%
Q1 24
-82.4%
-1943.4%
EPS (diluted)
CISO
CISO
RNA
RNA
Q4 25
$0.10
Q3 25
$-0.05
$-1.27
Q2 25
$-0.09
$-1.21
Q1 25
$-0.38
$-0.90
Q4 24
$-0.47
$-0.80
Q3 24
$-0.32
$-0.65
Q2 24
$-0.69
$-0.65
Q1 24
$-0.55
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CISO
CISO
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$1.7M
$350.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$14.8M
$1.9B
Total Assets
$25.0M
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CISO
CISO
RNA
RNA
Q4 25
$1.7M
Q3 25
$1.1M
$350.2M
Q2 25
$760.8K
$243.9M
Q1 25
$1.8M
$254.2M
Q4 24
$992.6K
$219.9M
Q3 24
$443.1K
$370.2M
Q2 24
$1.1M
$575.8M
Q1 24
$1.5M
$471.4M
Total Debt
CISO
CISO
RNA
RNA
Q4 25
Q3 25
$2.1M
Q2 25
$9.9M
Q1 25
$10.6M
Q4 24
$11.7M
Q3 24
$11.9M
Q2 24
$12.8M
Q1 24
$15.1M
Stockholders' Equity
CISO
CISO
RNA
RNA
Q4 25
$14.8M
Q3 25
$16.3M
$1.9B
Q2 25
$7.6M
$1.2B
Q1 25
$7.0M
$1.3B
Q4 24
$1.1M
$1.4B
Q3 24
$3.0M
$1.5B
Q2 24
$5.6M
$1.2B
Q1 24
$11.2M
$830.9M
Total Assets
CISO
CISO
RNA
RNA
Q4 25
$25.0M
Q3 25
$25.1M
$2.1B
Q2 25
$25.8M
$1.4B
Q1 25
$27.8M
$1.5B
Q4 24
$26.7M
$1.6B
Q3 24
$26.6M
$1.6B
Q2 24
$43.2M
$1.3B
Q1 24
$47.5M
$951.5M
Debt / Equity
CISO
CISO
RNA
RNA
Q4 25
Q3 25
0.13×
Q2 25
1.31×
Q1 25
1.52×
Q4 24
10.20×
Q3 24
3.92×
Q2 24
2.27×
Q1 24
1.35×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CISO
CISO
RNA
RNA
Operating Cash FlowLast quarter
$-1.8M
$-156.2M
Free Cash FlowOCF − Capex
$-156.9M
FCF MarginFCF / Revenue
-1257.6%
Capex IntensityCapex / Revenue
5.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CISO
CISO
RNA
RNA
Q4 25
$-1.8M
Q3 25
$-876.7K
$-156.2M
Q2 25
$-2.3M
$-199.7M
Q1 25
$-3.0M
$-124.8M
Q4 24
$-259.0K
$-99.9M
Q3 24
$-903.1K
$-65.6M
Q2 24
$-1.3M
$-65.0M
Q1 24
$-1.4M
$-70.4M
Free Cash Flow
CISO
CISO
RNA
RNA
Q4 25
Q3 25
$-156.9M
Q2 25
$-203.0M
Q1 25
$-128.6M
Q4 24
$-103.8M
Q3 24
$-67.3M
Q2 24
$-1.3M
$-65.5M
Q1 24
$-1.5M
$-71.3M
FCF Margin
CISO
CISO
RNA
RNA
Q4 25
Q3 25
-1257.6%
Q2 25
-5277.1%
Q1 25
-8174.3%
Q4 24
-3491.0%
Q3 24
-2881.8%
Q2 24
-16.4%
-3204.6%
Q1 24
-18.5%
-2012.3%
Capex Intensity
CISO
CISO
RNA
RNA
Q4 25
Q3 25
5.7%
Q2 25
86.9%
Q1 25
238.6%
Q4 24
0.0%
131.7%
Q3 24
0.0%
72.9%
Q2 24
0.1%
26.0%
Q1 24
0.9%
25.8%
Cash Conversion
CISO
CISO
RNA
RNA
Q4 25
Q3 25
-0.35×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CISO
CISO

Security Managed Services$5.4M87%
Other$823.3K13%

RNA
RNA

Segment breakdown not available.

Related Comparisons